Incyte Research Development vs Net Interest Income Analysis
INCY Stock | USD 57.05 0.55 0.95% |
Incyte financial indicator trend analysis is infinitely more than just investigating Incyte recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Incyte is a good investment. Please check the relationship between Incyte Research Development and its Net Interest Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Research Development vs Net Interest Income
Research Development vs Net Interest Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Incyte Research Development account and Net Interest Income. At this time, the significance of the direction appears to have strong relationship.
The correlation between Incyte's Research Development and Net Interest Income is 0.67. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Incyte, assuming nothing else is changed. The correlation between historical values of Incyte's Research Development and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Incyte are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Research Development i.e., Incyte's Research Development and Net Interest Income go up and down completely randomly.
Correlation Coefficient | 0.67 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Research Development
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most indicators from Incyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Incyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.At this time, Incyte's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 229.8 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.30 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 2.2B | 2.6B | 2.8B | 2.9B | Cost Of Revenue | 151.0M | 207.0M | 255M | 267.8M |
Incyte fundamental ratios Correlations
Click cells to compare fundamentals
Incyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Incyte fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Short Long Term Debt Total | 50.9M | 34.9M | 34.3M | 44.6M | 38.3M | 36.4M | |
Other Current Liab | 76.1M | 86.2M | 82.8M | 469.7M | 111.7M | 70.6M | |
Total Current Liabilities | 500.5M | 648.8M | 885.1M | 1.2B | 1.2B | 1.3B | |
Total Stockholder Equity | 2.6B | 2.6B | 3.8B | 4.4B | 5.2B | 5.4B | |
Property Plant And Equipment Net | 406.6M | 588.1M | 751.5M | 765.6M | 777.0M | 815.9M | |
Net Debt | (1.8B) | (1.5B) | (2.0B) | (2.9B) | (3.2B) | (3.0B) | |
Retained Earnings | (1.4B) | (1.7B) | (777.9M) | (437.2M) | 160.4M | 168.4M | |
Accounts Payable | 83.6M | 98.8M | 172.1M | 277.5M | 109.6M | 115.1M | |
Cash | 1.8B | 1.5B | 2.1B | 3.0B | 3.2B | 3.4B | |
Non Current Assets Total | 889.7M | 1.1B | 1.7B | 1.6B | 2.1B | 2.2B | |
Cash And Short Term Investments | 2.1B | 1.8B | 2.3B | 3.2B | 3.7B | 3.8B | |
Common Stock Shares Outstanding | 217.7M | 218.1M | 222.1M | 224.0M | 225.9M | 130.7M | |
Liabilities And Stockholders Equity | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
Non Current Liabilities Total | 327.9M | 300.9M | 278.3M | 254.3M | 351.9M | 340.4M | |
Other Current Assets | 94.2M | 103.3M | 165.3M | 167.0M | 182.8M | 192.0M | |
Other Stockholder Equity | 4.0B | 4.4B | 4.6B | 4.8B | 5.0B | 5.3B | |
Total Liab | 828.3M | 949.7M | 1.2B | 1.5B | 1.6B | 1.7B | |
Total Current Assets | 2.5B | 2.4B | 3.2B | 4.2B | 4.6B | 4.9B | |
Short Term Debt | 28.3M | 15.0M | 13.2M | 11.4M | 9.1M | 8.7M | |
Non Currrent Assets Other | 55.6M | 62.8M | 68.1M | 106.1M | 260.9M | 274.0M | |
Net Receivables | 308.8M | 482.0M | 616.3M | 644.9M | 743.6M | 780.7M | |
Property Plant And Equipment Gross | 406.6M | 559.6M | 751.5M | 765.6M | 1.0B | 1.1B | |
Accumulated Other Comprehensive Income | (15.5M) | (15.4M) | (19.5M) | 15.1M | 13.1M | 13.8M | |
Intangible Assets | 193.8M | 172.3M | 150.8M | 129.2M | 123.5M | 74.2M | |
Short Term Investments | 284.9M | 288.4M | 290.8M | 287.5M | 442.7M | 464.8M | |
Other Assets | 55.6M | 25.1M | 467.5M | 564.0M | 648.6M | 681.1M | |
Common Stock Total Equity | 216K | 219K | 221K | 223K | 256.5K | 154K | |
Common Stock | 216K | 219K | 221K | 223K | 224K | 157.9K | |
Property Plant Equipment | 377.6M | 559.6M | 723.9M | 739.3M | 850.2M | 892.7M | |
Current Deferred Revenue | 312.4M | 448.9M | 617.0M | 457.9M | 1.0B | 1.1B | |
Other Liab | 271.2M | 266M | 244M | 269.6M | 310.0M | 156.9M | |
Inventory | 16.5M | 36.0M | 56.9M | 121.0M | 63.0M | 66.1M | |
Net Tangible Assets | 2.2B | 2.3B | 3.5B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.4B) | (1.7B) | (777.9M) | (437.2M) | (502.8M) | (527.9M) | |
Capital Surpluse | 4.0B | 4.4B | 4.6B | 4.8B | 5.5B | 3.4B | |
Non Current Liabilities Other | 315.0M | 318.5M | 309.0M | 313.8M | 322.7M | 278.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.705 | Earnings Share 3.3 | Revenue Per Share 16.82 | Quarterly Revenue Growth 0.089 | Return On Assets 0.0689 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.